Equities Analysts Set Expectations for EyePoint Pharmaceuticals, Inc.’s FY2023 Earnings (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Rating) – Chardan Capital raised their FY2023 earnings per share estimates for EyePoint Pharmaceuticals in a note issued to investors on Sunday, May 21st. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings per share of ($0.52) for the year, up from their prior estimate of ($2.54). The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($1.67) per share. Chardan Capital also issued estimates for EyePoint Pharmaceuticals’ FY2024 earnings at ($2.47) EPS.

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) last posted its earnings results on Thursday, March 2nd. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.02. The company had revenue of $10.53 million for the quarter, compared to analysts’ expectations of $9.71 million. EyePoint Pharmaceuticals had a negative return on equity of 70.70% and a negative net margin of 257.44%.

Several other analysts have also recently issued reports on EYPT. StockNews.com raised EyePoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. HC Wainwright raised their target price on EyePoint Pharmaceuticals from $25.00 to $27.00 in a research note on Friday, May 19th. Finally, Robert W. Baird assumed coverage on EyePoint Pharmaceuticals in a research note on Thursday, April 20th. They issued an “outperform” rating and a $33.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $33.50.

EyePoint Pharmaceuticals Stock Down 5.4 %

NASDAQ EYPT opened at $5.93 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.36 and a quick ratio of 5.21. The stock has a market capitalization of $203.40 million, a PE ratio of -2.17 and a beta of 1.12. EyePoint Pharmaceuticals has a 1 year low of $2.19 and a 1 year high of $11.44. The business’s 50-day moving average is $5.03 and its 200 day moving average is $4.12.

Institutional Trading of EyePoint Pharmaceuticals

Several large investors have recently bought and sold shares of EYPT. Caligan Partners LP bought a new stake in EyePoint Pharmaceuticals during the 4th quarter valued at approximately $1,524,000. Bank of America Corp DE lifted its holdings in shares of EyePoint Pharmaceuticals by 3,306.1% during the fourth quarter. Bank of America Corp DE now owns 338,596 shares of the company’s stock valued at $1,185,000 after purchasing an additional 328,655 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 64.6% during the fourth quarter. Millennium Management LLC now owns 675,433 shares of the company’s stock valued at $2,364,000 after purchasing an additional 265,147 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of EyePoint Pharmaceuticals by 40.0% during the first quarter. Goldman Sachs Group Inc. now owns 871,101 shares of the company’s stock valued at $10,584,000 after purchasing an additional 249,083 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of EyePoint Pharmaceuticals by 2.9% during the fourth quarter. Franklin Resources Inc. now owns 5,774,509 shares of the company’s stock valued at $20,211,000 after purchasing an additional 164,632 shares during the last quarter. 88.27% of the stock is owned by institutional investors.

About EyePoint Pharmaceuticals

(Get Rating)

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.